Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa

The Lancet Infectious Diseases

Volumn 16, Issue 11, 2016, Pages e267-e275

  Inzaule, Seth C ^a,b   Ondoa, Pascale ^a,b   Peter, Trevor ^d,e   Mugyenyi, Peter N ^c   Stevens, Wendy S ^f   de Wit, Tobias F Rinke ^a,b   Hamers, Raph L ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d African Society for Laboratory Medicine   (Ethiopia)

^e CLINTON HEALTH ACCESS INITIATIVE   (United States)

^f NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CENTRALIZATION; DRUG MONITORING; DRUG TREATMENT FAILURE; GENOTYPE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY; LABORATORY TEST; NEXT GENERATION SEQUENCING; NONHUMAN; PATIENT CARE; POINT MUTATION; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VIRUS LOAD; WORLD HEALTH ORGANIZATION; DRUG EFFECTS; ECONOMICS; EPIDEMIOLOGY; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MASS SCREENING; MUTATION; PROCEDURES;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; MASS SCREENING; MUTATION; VIRAL LOAD;

EID: 84994176567     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30118-9     Document Type: Review

References (73)

1. 1 UNAIDS. How AIDS changed everything- MDG6: 15 years, 15 lessons of hope from the AIDS response, 2015, UN, New York City http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf (accessed April 5, 2016).
2. 2 UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic, 2014, UN, New York City http://www.unaids.org/en/resources/documents/2014/90-90-90 (accessed Feb 1, 2016).
3. 3 Wamalwa, DC, Lehman, DA, Benki-Nugent, S, et al. Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy. J Acquir Immune Defic Syndr 62 (2013), 267–274.
4. 4 Boender, TS, Sigaloff, KC, McMahon, JH, et al. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis 61 (2015), 1453–1461.
5. 5 Hamers, RL, Sigaloff, KC, Wensing, AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 54 (2012), 1660–1669.
6. 6 Sigaloff, KCE, Calis, JCJ, Geelen, SP, van Vugt, M, de Wit, TFR, HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis 11 (2011), 769–779.
7. 7 The TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis 16 (2016), 565–575.
8. 8 WHO. WHO HIV drug resistance report 2012, 2012, WHO, Geneva http://apps.who.int/iris/bitstream/10665/75183/1/9789241503938_eng.pdf (accessed March 22, 2016).
9. 9 Gupta, RK, Jordan, MR, Sultan, BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 380 (2012), 1250–1258.
10. 10 Hoare, A, Kerr, SJ, Ruxrungtham, K, et al. Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLoS One, 5, 2010, e10981.
11. 11 Rhee, SY, Blanco, JL, Jordan, MR, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of Ttransmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med, 12, 2015, e1001810.
12. 12 Wittkop, L, Günthard, HF, de Wolf, F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11 (2011), 363–371.
13. 13 Hamers, RL, Schuurman, R, Sigaloff, KC, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 12 (2012), 307–317.
14. 14 Estill, J, Ford, N, Salazar-Vizcaya, L, et al. The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study. Lancet HIV 3 (2016), e132–e139.
15. 15 Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2016, NIH, New York City https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0 (accessed April 4, 2016).
16. 16 European AIDS Clinical Society. European treatment guidelines V 8.0. 2015. http://www.eacsociety.org/files/2015_eacsguidelines_8_0-english_rev-20160124.pdf (accessed April 04, 2016).
17. 17 Medecins Sans Frontieres Access Campaign. Decisions around HIV treatment in 2015: Seven ways to fail, derail or prevail, 2015, Medecins Sans Frontieres, Geneva http://www.msfaccess.org/sites/default/files/HIV_Brief_HIV_Fail_Derail_or_Prevail_ENG_2015.pdf (accessed March 24, 2016).
18. 18 WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: What's new, 2015, WHO, Geneva http://apps.who.int/iris/bitstream/10665/198064/1/9789241509893_eng.pdf (accessed March 24, 2016).
19. 19 Wainberg, MA, Mesplede, T, Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy. J Int AIDS Soc, 18, 2015, 20824.
20. 20 Ford, N, Stinson, K, Gale, H, et al. CD4 changes among virologically suppressed patients on antiretroviral therapy: a systematic review and meta-analysis. J Int AIDS Soc, 18, 2015, 20061.
21. 21 UNAIDS. Diagnostics access initiative to achieve the 90-90-90 treatment target, 2015, UN, New York City http://www.unaids.org/sites/default/files/media_asset/20150422_diagnostics_access_initiative.pdf (accessed April 5, 2016).
22. 22 WHO. HIV drug resistance surveillance guidance: 2015 update, 2015, WHO, Geneva http://apps.who.int/iris/bitstream/10665/204471/1/9789241510097_eng.pdf?ua=1 (accessed March 22, 2016).
23. 23 Ministry of Health. Botswana national HIV & Treatment Guidelines 2008, 2008, Botswana Ministry of Health, Gabarone www.moh.gov.bw/Publications/HIVAIDS%20TREATMENT%20GUIDELINES.pdf (accessed Sept 29, 2015).
24. 24 Ministry of Health National AIDS and STI Control Program (NASCOP). Guidelines on use of antiretroviral drugs for treating and preventing HIV infection: a rapid advice, 2014, 2014, NASCOP, Nairobi http://healthservices.uonbi.ac.ke/sites/default/files/centraladmin/healthservices/RapidAdviceBooklet201424June12%20noon_0.pdf (accessed Sept 29, 2015).
25. 25 Conradie, F, Wilson, D, Basson, A, et al. The 2012 southern African ARV drug resistance testing guidelines. SAfr J HIV Med 13 (2012), 162–167.
26. 26 Baxter, JD, Mayers, DL, Wentworth, DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14 (2000), F83–F93.
27. 27 Tural, C, Ruiz, L, Holtzer, C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16 (2002), 209–218.
28. 28 Cingolani, A, Antinori, A, Rizzo, MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 16 (2002), 369–379.
29. 29 Weinstein, MC, Goldie, SJ, Losina, E, et al. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med 134 (2001), 440–450.
30. 30 Sax, PE, Islam, R, Walensky, RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 41 (2005), 1316–1323.
31. 31 Gupta, RK, Hill, A, Sawyer, AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 9 (2009), 409–417.
32. 32 Steegen K, Bronze M, Papathanasopoulos MA, et al. Prevalence of protease inhibitor and triple-class resistance in patients failing 2nd-line ART: results from a national survey in South Africa. 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015); July 19–22, 2015; Vancouver, BC, Canada. TUPEB289.
33. 33 Ajose, O, Mookerjee, S, Mills, EJ, Boulle, A, Ford, N, Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 26 (2012), 929–938.
34. 34 Boender, TS, Hamers, RL, Ondoa, P, et al. Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa. J Infect Dis, 2016, 10.1093/infdis/jiw219 published online July 11, 2016.
35. 35 Levison, JH, Wood, R, Scott, CA, et al. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Clin Infect Dis 56 (2013), 587–597.
36. 36 Rosen, S, Long, L, Sanne, I, Stevens, WS, Fox, MP, The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc, 14, 2011, 24.
37. 37 Phillips, A, Cambiano, V, Nakagawa, F, et al. Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. PLoS One, 9, 2014, e109148.
38. 38 Lorenzana, SB, Hughes, MD, Grinsztejn, B, et al. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. Aids 26 (2012), 1083–1093.
39. 39 Emmadi, R, Boonyaratanakornkit, JB, Selvarangan, R, et al. Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays. J Mol Diagn 13 (2011), 583–604.
40. 40 Aitken, SC, Bronze, M, Wallis, CL, et al. A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only. J Clin Microbiol 51 (2013), 1757–1761.
41. 41 Manasa, J, Danaviah, S, Pillay, S, et al. An affordable HIV-1 drug resistance monitoring method for resource limited settings. J Vis Exp, 85, 2014, 51242.
42. 42 Monleau, M, Aghokeng, AF, Eymard-Duvernay, S, et al., for the ANRS 12235 Study Group. Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia. J Clin Microbiol 52 (2014), 578–586.
43. 43 Zhou, Z, Wagar, N, DeVos, JR, et al. Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLoS One, 6, 2011, e28184.
44. 44 Bioafrica. SATuRN and Life Technologies (ABI) partnership provide a discounted HIV resistance genotyping system. http://www.bioafrica.net/report.php?id=8 (accessed April 4, 2016).
45. 45 ATCC. HIV-1 drug resistance genotyping kit. http://www.atcc.org/HIVkits (accessed April 4, 2016).
46. 46 Newman, H, Breunig, L, van Zyl, G, Stich, A, Preiser, W, A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy. J Clin Virol 60 (2014), 387–391.
47. 47 Hamers, RL, Smit, PW, Stevens, W, Schuurman, R, Rinke de Wit, TF, Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther 14 (2009), 619–629.
48. 48 Bertagnolio, S, Parkin, NT, Jordan, M, Brooks, J, Garcia-Lerma, JG, Dried blood spots for HIV-1 drug resistance and viral load testing: a review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev 12 (2010), 195–208.
49. 49 Illumina. Next-generation sequencing instruments. http://www.captodayonline.com/2014/ProductGuides/11-14_CAPTODAY_NextGenSequencing.pdf (accessed April 4, 2016).
50. 50 Ekici, H, Rao, SD, Sönnerborg, A, Ramprasad, VL, Gupta, R, Neogi, U, Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries. J Antimicrob Chemother 69 (2014), 3349–3355.
51. 51 Dudley, DM, Chin, EN, Bimber, BN, et al. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One, 7, 2012, e36494.
52. 52 Giandhari, J, Basson, AE, Sutherland, K, et al. Contribution of gag and protease to HIV-1 phenotypic drug resistance in paediatric patients failing protease-inhibitor based therapy. Antimicrob Agents Chemother, 2016, 10.1128/AAC.02682-15 published online Feb 1.
53. 53 Rabi, SA, Laird, GM, Durand, CM, et al. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest 123 (2013), 3848–3860.
54. 54 Gibson, RM, Meyer, AM, Winner, D, et al. Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. Antimicrob Agents Chemother 58 (2014), 2167–2185.
55. 55 Ji, H, Li, Y, Graham, M, et al. Next-generation sequencing of dried blood spot specimens: a novel approach to HIV drug-resistance surveillance. Antivir Ther 16 (2011), 871–878.
56. 56 Sboner, A, Mu, XJ, Greenbaum, D, Auerbach, RK, Gerstein, MB, The real cost of sequencing: higher than you think!. Genome Biol, 12, 2011, 125.
57. 57 Quail, MA, Smith, M, Coupland, P, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics, 13, 2012, 341.
58. 58 Loman, NJ, Misra, RV, Dallman, TJ, et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 30 (2012), 434–439.
59. 59 Nakamura, K, Oshima, T, Morimoto, T, et al. Sequence-specific error profile of Illumina sequencers. Nucleic Acids Res, 39, 2011, e90.
60. 60 Rhee, SY, Jordan, MR, Raizes, E, et al. HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing. PLoS One, 10, 2015, e0145772.
61. 61 Zhang, G, Cai, F, Zhou, Z, et al. Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay. J Clin Microbiol 51 (2013), 3666–3674.
62. 62 Troyer, RM, Lalonde, MS, Fraundorf, E, et al. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS Res Hum Retroviruses 24 (2008), 235–250.
63. 63 Shi, C, Eshleman, SH, Jones, D, et al. LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 1 (2004), 141–147.
64. 64 Servais, J, Lambert, C, Fontaine, E, et al. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol 39 (2001), 454–459.
65. 65 Rowley, CF, Boutwell, CL, Lockman, S, Essex, M, Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C. J Virol Methods 149 (2008), 69–75.
66. 66 Masimba, P, Gare, J, Klimkait, T, Tanner, M, Felger, I, Development of a simple microarray for genotyping HIV-1 drug resistance mutations in the reverse transcriptase gene in rural Tanzania. Trop Med Int Heal 19 (2014), 664–671.
67. 67 Lee, JH, Hachiya, A, Shin, SK, et al. Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients. Clin Microbiol Infect 19 (2013), E263–E270.
68. 68 MacLeod IJ, Rowley CF, Essex M. Pan degenerate amplification and adaptation for highly sensitive detection of ARV drug resistance. Conference on Retroviruses and Opportunistic Infections (CROI 2014); Boston, MA, USA; March 3–6, 2014: abstr 606.
69. 69 Panpradist, N, Beck, IA, Chung, MH, Kiarie, JN, Frenkel, LM, Lutz, BR, Simplified paper format for detecting HIV drug resistance in clinical specimens by oligonucleotide ligation. PLoS One, 11, 2016, e0145962.
70. 70 WHO. Meeting report on WHO ResNet annual meeting. Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/75190/1/9789241503969_eng.pdf?ua=1, 2012 (accessed March 22, 2016).
71. 71 Revell, AD, Wang, D, Wood, R, et al. An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. J Antimicrob Chemother, 2016, 10.1093/jac/dkw217 published online Jun 20.
72. 72 Lessells, RJ, Avalos, A, de Oliveira, T, Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges. AIDS Rev 15 (2013), 221–229.
73. 73 WHO. Global action plan for HIV drug resistance 2016-2021. http://apps.who.int/iris/bitstream/10665/204518/1/WHO_HIV_2016.02_eng.pdf, 2016 (accessed April 7, 2016).